20th Annual Meeting of the Japanese Society of Clinical
Neuropsychopharmacology joint with 40th Annual Meeting of Japanese Society of Newropsychopharmacology

September 15-17, 2010
SENDAI INTERNATIONAL CENTER , Sendai, Japan

FIRST AUTHOR INDEX
First Name	Last Name	No.	Title
Leif	Bertilsson	SL1	History of pharmacogenetics in relation to clinical psychopharmacology
R Uhl	George	SL-2	Genome wide association data and Neuropsychopharmacology
Addington	Donald	CL-1	Recognition and Treatment of Depression in Schizophrenia
OGO	MAKOTO	S4-4	Recent progress of disease-modifying approach to the treatment for Alzheimer’s disease
Takahashi	Hidehiko	S9-4	Prospects for the understanding impairments of social emotions in neuropsychiatric disorders
Tomotake	Masahito	S11-1	Relation among cognitive dysfunction, quality of life and clinical symptoms in schizophrenia patients
Sumiyoshi	Tomiki	S11-2	Neurophysiological basis for cognitive defi cits of schizophrenia and effect of psychotropic drugs
Green	Michael	S11-3	Social cognition in schizophrenia: Why is it important and how can we improve it?
Spina	Edoardo	LS1	Clinically relevant drug interactions with newer antidepressants
F. Green	Michael	LS2	Drug treatments for cognitive impairment in schizophrenia
Bertilsson	Leif	LS5	Antidepressant drugs – Pharmacogenetics and drug-drug interactions
Addington	Donald	LS6	Recognition and Treatment of Patients at Clinical High Risk for Developing Schizophrenia
Tanabe	Yoichiro	O1-B3	Examination of the comprehensive gene expression in the SK-S-SH cell by the LTG dosage
Yoshimura	Reiji	O1-C3	Effi cacies of a low dose atypical antipsychotic drug addition to an antidepressant and its effects on plasma brain-derived neurotrophic factor levels in refractory depression
Nakajima	Shinichiro	O1-C4	Benefi ts of Switching Antidepressants Following Early Nonresponse
Takeuchi	Hiroyoshi	O1-D6	How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review
Uchida	Hiroyuki	O2-F1	Predicting Antipsychotic Plasma Concentrations Before Titrating The Dose: A Population Pharmacokinetic Study
Unemura	Kazuhiro	O2-I 4	Glucocorticoid-induced inhibition of astrocytic proliferation by the decrease of the expression of glucocorticoid receptor in cortical culture
Furuyashiki	Tomoyuki	O3-L4	Roles of prostaglandin E2 and its receptor EP1 in adaptive selection of emotional behaviors
H Kalali	Amir	O3-N4	Crisis in CNS Drug Development: Current Challenges and Possible Solutions
Takano	Katsura	O3-P5	A dibenzoylmethane derivative inhibits lipopolysaccharide-induced NO production in cultured rat astrocytes
Suzuki	Yutaro	P1-AVIII2	The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients
Ishitobi	Makoto	P1-B2	Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia
Matsuoka	Tadasu	P1-C3	Change in the expressions of myelination/oligodendrocyte- related genes during puberty in the rat brain
Kawagoe	Hirofumi	P1-F5	Promoted expression of glia-derived neurotrophic factor in cultured rat cortical astrocytesexposed to nicotine
Kato	Masaki	P1-HI5	New functional variant in SLC6A4 gene as candidate of the individualized treatment of depression -The result of RCT-
Kerise	Lyttle	P1-K2	Effects of liquiritigenin and iso-liquiritigenin, which are isolated from Glycyrrhiza, on a menopausal depressive-like state in ovariectomized mice
Yoshimura	Hiroyuki	P1-K3	Psychopharmacological identifi cation of a new antidepressant-like component, (E)-9,10-dihydroxy-2-decenoic acid, from Honeybee royal jelly
Sugimoto	Yumi	P1-K4	Involvement of the sigma receptor in in anti-immobility effects of fl uvoxamine in mice
Rahmadi	Mahardian	P1-K5	Studies on drug dependence (Rept. 443): Research for the molecular mechanisms underlying sleep disturbance induced by chronic treatment wit SSRI and SNRI
Miller	David	P1-O4	Improving Data Quality Throughout the Course of Global Alzheimer’s Trials
KONISHI	SHIHO	P1-RI3	Responsiveness of Ifrd1 as a differentiation regulator in neural progenitors to brain ischemia
SHIBA	TATSUO	P1-RI6	Regulation by ryanodine receptors of proliferative activity in neural stem/ progenitor cells derived from subventricular zone of adult mice
Oshimo	Takashi	P2-AII3	The effectiveness and safety of blonanserin in drugnaive patients with schizophrenia: An open label trial
Kato	Masaki	P2-AIII1	Lurasidone in the Treatment of Acute Schizophrenia: Results of the Double- Blind, Placebo-Controlled PEARL 2 Trial
Takekita	Yoshiteru	P2-AIII2	Effi cacy and Safety of Lurasidone in Schizophrenia: Results of a Phase 2, Placebo-Controlled, Study
Morita	Michiaki	P2-AV4	Silent extrapyramidal syndrome induced by aripiprazole
Nakano	Wakako	P2-AIX2	Reductions of polypharamacies of antipsychotic drugs with high dose in Japan; results from the REAP-3 study
Tadori	Yoshihiro	P2-D1	Action of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors
Umezu	Toyoshi	P2-G6	Behavioral pharmacology of plant-derived substances (23): Effects of essential oils on ambulation in mice. Comparison with their effects on Shuttle type conditioned avoidance response
Nakayama	Yukari	P2-G7	Behavioral changes and neural regeneration after hippocampal dentate injury in mice
Iga	Junichi	P2-L1	Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and bipolar patients
Ikenouchi-Sugita	Atsuko	P2-N1	No association between polymorphisms of Brain-derived neurotrophic factor (BDNF) Val66Met and psychiatric symptoms in systemic lupus erythematosus
Nishimura	Katsuji	P2-N2	Risperidone in the treatment of corticosteroid-induced mood disorders in systemic lupus erythematosus: a case series
Kuroiwa	Mahomi	P2-RII1	Role of phosphodiesterase 4 in dopamine D1 receptor/cAMP/PKA signaling in the frontal cortex
Sako	Aya	P2-RII6	Translocation of glutamine transporter expressed in C6 glioma cells
Nishizawa	Daisuke	P2-RII7	Association between GIRK3 gene polymorphisms and postoperative analgesic requirements after major abdominal surgery